List of Exservan drug patents

Exservan is owned by Mitsubishi Holdings.

Exservan contains Riluzole.

Exservan has a total of 2 drug patents out of which 0 drug patents have expired.

Exservan was authorised for market use on 22 November, 2019.

Exservan is available in film;oral dosage forms.

The generics of Exservan are possible to be released after 03 April, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 MITSUBISHI HOLDINGS Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(1 year, 17 days from now)

US8603514 MITSUBISHI HOLDINGS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(1 year, 1 month from now)

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic